NASDAQ · BCRX
Healthcare · Biotechnology
$8.16
Up+$0.10 (+1.26%)
Updated Sep 16, 2026, 5:22 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BCRX closed at $8.16 after 20 trading sessions, down 15.88% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $8.19 | $8.23 | $8.0201 | $8.16 | 6.11M |
| Sep 14, 2026 | $8.17 | $8.38 | $8.095 | $8.23 | 5.1M |
| Sep 11, 2026 | $8.30 | $8.3972 | $8.105 | $8.12 | 3.59M |
| Sep 10, 2026 | $8.34 | $8.46 | $8.045 | $8.29 | 9M |
| Sep 9, 2026 | $9.07 | $9.23 | $8.80 | $8.805 | 5.15M |
| Sep 8, 2026 | $9.122 | $9.40 | $8.96 | $9.065 | 9.69M |
| Sep 4, 2026 | $10.00 | $10.10 | $9.895 | $9.96 | 1.5M |
| Sep 3, 2026 | $10.15 | $10.22 | $9.935 | $10.09 | 1.97M |
| Sep 2, 2026 | $10.00 | $10.23 | $9.83 | $10.17 | 3.13M |
| Sep 1, 2026 | $9.72 | $9.955 | $9.63 | $9.92 | 3.37M |
| Aug 31, 2026 | $9.72 | $9.72 | $9.46 | $9.70 | 2.76M |
| Aug 28, 2026 | $9.822 | $9.96 | $9.72 | $9.82 | 2.7M |
| Aug 27, 2026 | $9.75 | $9.92 | $9.551 | $9.87 | 2.48M |
| Aug 26, 2026 | $9.77 | $9.90 | $9.71 | $9.83 | 1.86M |
| Aug 25, 2026 | $9.79 | $9.9161 | $9.698 | $9.83 | 2.33M |
| Aug 24, 2026 | $9.50 | $9.755 | $9.48 | $9.68 | 2.01M |
| Aug 21, 2026 | $9.72 | $9.905 | $9.48 | $9.55 | 2.5M |
| Aug 20, 2026 | $9.92 | $9.9883 | $9.595 | $9.66 | 2.33M |
| Aug 19, 2026 | $9.93 | $10.11 | $9.765 | $10.07 | 2.91M |
| Aug 18, 2026 | $9.89 | $9.94 | $9.545 | $9.70 | 2.12M |
The latest Smart Investors Daily articles mentioning BCRX.
BCRX research
Company profile and research snapshot.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | RBC Capital | Sector Perform | — |
| Sep 8, 2026 | Needham | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | Wedbush | Outperform | — |
| Jul 13, 2026 | JP Morgan | Neutral | — |
Generated Sep 16, 2026, 3:08 PM
BioCryst Pharmaceuticals is trading slightly lower today despite positive developments around its flagship product ORLADEYO. The modest 0.37% decline suggests investors are taking a measured approach as the company presents at a major healthcare conference while analysts highlight significant upside potential in the stock's valuation.
Bottom line: BCRX presents an interesting risk-reward scenario with analysts identifying significant undervaluation relative to ORLADEYO's growth potential, yet today's modest decline suggests the market remains unconvinced without concrete execution evidence. Investors should monitor upcoming commercial metrics and pipeline developments closely, as successful ORLADEYO momentum could provide meaningful upside, while any disappointing growth trends would validate current cautious positioning.
SeekingAlpha · Sep 15, 2026
BioCryst Pharmaceuticals, Inc. (BCRX) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 9:15 AM EDTCompany ParticipantsCharles...
Yahoo · Sep 14, 2026
BioCryst Pharmaceuticals (BCRX) has drawn fresh attention after recent trading left the share price at US$8.12, with the stock down over the past week and month but modestly higher year to date. Recent trading tells a mixed story for BioCryst Pharmaceuticals, with the share price falling 18.47% over the past week and 16.63% over the past month, yet still showing an 8.27% year to date share price return and a 5.45% one year total shareholder return. This suggests that short term momentum is...
SeekingAlpha · Sep 11, 2026
BioCryst Pharmaceuticals, Inc. stock update: Orladeyo Q2 revenue rose 6.7%, debt fell, and navenibart adds HAE upside. Click for more on BCRX.
Yahoo · Sep 10, 2026
Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index shedding 0.2% and the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BCRX.
